NewsBenzingaRBC Capital maintient sa recommandation « Surperformance » sur Vertex Pharmaceuticals et relève son objectif de cours à 600 $ RBC Capital maintient sa recommandation « Surperformance » sur Vertex Pharmaceuticals et relève son objectif de cours à 600 $ Benzinga 2026.11.03 15:13 (GMT+0) Open on Benzinga Other news AMD Gained From Nvidia’s China Scandal. Now a Short Seller Says AMD Has a China Problem Too. Dell Could Swing $25.2 Billion After Earnings Report Says UK to Ban Crypto Exchanges From Market Making on Their Own Platforms Wall Street Brunch: Can AI Bulls Get Up Off The Canvas? AI Rout Turns Gold Into Source Of Cash: What Comes Next? Leadership Risk vs. Record Numbers: Nvidia Posted $115 Billion in Revenue in Its First Report Without Jensen Huang. What It Means for NVDA Stock.
Leadership Risk vs. Record Numbers: Nvidia Posted $115 Billion in Revenue in Its First Report Without Jensen Huang. What It Means for NVDA Stock.